glutathione meniere's disease and neurodegenerative diseases: immunopharmacological implications SPI-1005 for Meniere's Disease ·
SPI 1005 for Meniere's Disease Info for Participants Phase Phase 3 Clinical Trial 2026 Power Power Several lines of antioxidant defense against oxidative stress: antioxidant enzymes, nanomaterials with multiple enzyme mimicking activities, and low molecular weight antioxidants Archives of Toxicology Springer Nature Link Sound Pharmaceuticals concludes subject enrolment for SPI 1005 trial Meniere disease and ebselen: anti neoplastic may help manage symptoms
Pay in 4 interest-free payments of $6.08 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



